We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
By adding the name "Kolon," the new corporate identity recognizes the patient but committed support and effort by its parent company and major shareholder, the Kolon Group.
The grant award will be used by TissueGene to fund a component of a clinical study at a Maryland location for its US Phase III clinical trial for Invossa.